SCHEMBL2185663

SCHEMBL2185663

NC(=O)c1c(C(=O)O)cc(Br)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 1/20 0.46
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP2C9 P11712 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MCL1 Q07820 1/20 0.41
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
GRM2 Q14416 1/20 0.40
HPGD P15428 4/20 0.40
THRB P10828 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
ATIC P31939 1/20 0.40
ALDH1A1 P00352 4/20 0.39
NR4A1 P22736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27872697 0.89 ATM (0.42) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL9996096 0.87 PRNP (0.54) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL4830420 0.81 PRNP (0.45) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL1287803 0.79 PRNP (0.49) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL31178974 0.79 PRNP (0.49) PRNPKDM4EHSD17B10MEN1KMT2A
Bromide SCHEMBL17969006 0.77 PRNP (0.47) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL485235 0.77 HSD17B10 (0.67) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL10193950 0.77 PRNP (0.54) PRNPKDM4EHSD17B10MEN1KMT2A
SCHEMBL19423432 0.77 HSD17B10 (0.47) KDM4EHSD17B10MEN1KMT2ACYP2C9
SCHEMBL31667837 0.75 PRNP (0.49) PRNPKDM4EHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343279-B1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-8263622-B2 Fused-ring derivative and medical application of same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-25 US disclosed
EP-2343279-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME XDH, OAT, PON1 PRNP 1900/4885KDM4E 3834/4885HSD17B10 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.